Across TCGA pan-cancer cohorts, H2BC1 RNA differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of H2BC1’s most consistent transcriptional readouts.
The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where H2BC1 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types H2BC1 is over-expressed in tumor.
LIHC and LUAD are the cancer types where H2BC1 tumor–normal differential expression is most reproducible.